Introduction

Every safe red cell transfusion depends on matching the donor unit not just to the patient's ABO and Rh type, but to any extra antibodies the patient may have made against other red cell antigens. Antibody identification is the laboratory procedure that names those antibodies.

It is the step that follows antibody screening. Screening asks a simple yes/no question: does the patient have a clinically significant red cell antibody? Identification answers the next question: which one? Getting this right matters. A missed alloantibody can cause a hemolytic transfusion reaction, where transfused red cells are destroyed by the recipient's immune system [8].

Antibodies relevant to transfusion fall into two broad groups. Isoagglutinins (anti-A and anti-B) occur naturally without prior red cell exposure. Alloantibodies are immune antibodies a person develops after exposure to foreign red cell antigens through transfusion, pregnancy, or fetomaternal hemorrhage (fetal red cells entering the maternal circulation). Common examples include anti-D, anti-K, anti-Jka, and anti-Fya. Antibody identification is concerned mainly with these alloantibodies, and occasionally with autoantibodies (antibodies a patient makes against their own red cells).

Principle of Antibody Identification

Antibody identification rests on antigen-antibody specificity. Each red cell carries surface antigens from many blood group systems, including Rh, ABO, and minor blood groups like Duffy, Kidd, and MNS. If a person has been exposed to a foreign antigen and has produced an antibody against it, that antibody will bind specifically to red cells carrying that antigen.

A positive antibody screen tells us an antibody is there. It does not tell us what it targets. To find out, the patient's plasma is tested against a panel of well-characterized group O red cells. Each panel cell has a published antigen profile shown on an antigram. By looking at which cells the patient's plasma reacted with, and which it did not, the antibody specificity can be deduced [2].

Group O cells are used so that ABO antibodies in the patient's plasma do not interfere with the reactions of interest.

The autocontrol

A tube containing the patient's plasma plus the patient's own red cells is always tested in parallel. This is the autocontrol. A negative autocontrol with positive panel reactions points to an alloantibody. A positive autocontrol points to an autoantibody, or to recently transfused donor cells now coated with the patient's antibody.

What an "identification" actually requires

To call an antibody confirmed, two things must be shown to ensure statistical validity [1]:

• The patient's plasma reacts with at least three panel cells that carry the suspected antigen (the "rule in").
• The patient's plasma does not react with at least three panel cells that lack the suspected antigen (the "rule out").

This 3-by-3 pattern (the Rule of 3) provides a 95% statistical confidence (p = 0.05) that the antibody specificity is correct, rather than a random occurrence. Where dosage matters (Kidd, Duffy, MNS, Ss), the rule-out cells must be homozygous for the antigen so that even a weak antibody has the best chance of being detected [1].

Phases of testing and what they reveal

Reading reactions at three phases helps separate clinically significant antibodies from those that usually are not:

• Immediate spin (room temperature): detects cold-reacting IgM antibodies (e.g. anti-M, anti-N, anti-P1, anti-Lewis).
• 37°C with enhancement (e.g. LISS): detects warm IgM and some IgG antibodies before the antiglobulin phase.
• Indirect antiglobulin test (IAT): detects IgG antibodies bound to red cells but not directly visible. This is the most clinically important phase because IgG antibodies cause hemolytic transfusion reactions and hemolytic disease of the fetus and newborn [8,9].

Materials

Routine antibody identification requires:

• Patient plasma or serum from 10 to 20 mL of anticoagulated blood, ideally less than three days old to preserve antibody and complement activity.
• A commercial panel of at least eight group O red cells with diverse antigen profiles across Rh, Kell, Duffy, Kidd, MNS, and Lewis systems.
• A 2–4% suspension of the patient's own red cells for the autocontrol.
• Anti-human globulin (AHG) reagent, polyspecific or IgG-specific depending on the lab.
• Coombs control cells (CCC) — IgG-coated red cells used to verify a negative antiglobulin reaction.
• Low ionic strength solution (LISS) as the enhancement medium.
• Enzyme-treated cells (papain or ficin) for selected cases, used to confirm or exclude Rh and Kidd antibodies and to remove Duffy, MNS, and Xga reactivity.
• Test tubes, calibrated micropipettes, a 37°C water bath or incubator, a serological centrifuge, and the antigram worksheet.

Reagent panel design

The cell panel must be built so it can both detect and exclude clinically significant antibodies. Following BSH guidance [2], an effective panel should include red cells with the following key Rh phenotypes:

• R₁R₁ (CDe/CDe) and R₁^wR₁ (CDe/C^wDe): These cells should collectively express antigens K, k, Fya, Fyb, Jka, Jkb, S, and s, which are targets for several significant antibodies. At least one example of each phenotype is required.
• R₂R₂(cDE/cDE), r’r (Cde/cde) and r”r (cdE/cde): These phenotypes provide additional antigen combinations for antibody detection. One example of each is needed.
• Minimum three rr (cde/cde) cells: These lack most Rh antigens but are crucial for excluding antibodies like anti-Jk^a, anti-Jk^b, etc. At least one K+ cell (expressing the Kell antigen) should be included among the three. Collectively, these rr cells should express all of k, Jk^a, Jk^b, S, s, Fy^a, and Fy^b in a double dose.

A single panel may not resolve every case. Best practice is to keep a second panel and a panel of enzyme-treated cells available, and to maintain panel cells under conditions that preserve antigenicity throughout their shelf life [2].

Protocol

The procedure below describes the conventional tube technique. Always follow the manufacturer's instructions for the specific panel and reagents in use. Many modern labs perform antibody identification using gel column agglutination or solid-phase red cell adherence instead of tubes; the principle is the same, but the read-out differs.

1. Label tubes for each panel cell plus one autocontrol tube.
2. Add two drops of patient plasma (or serum) to each tube.
3. Immediate spin phase (optional, room temperature): add one drop of the corresponding panel cell suspension, centrifuge, and read for agglutination or hemolysis. Record results in the IS column of the antigram.
4. Add two drops of LISS to each tube and mix.
5. 37°C phase: incubate all tubes at 37°C for 10–15 minutes, mixing gently as directed by the manufacturer.
6. Centrifuge and read for agglutination or hemolysis. Record in the 37°C column.
7. Antiglobulin phase: wash the red cells three times with saline, decanting completely after each wash to leave only the cell button.
8. Add two drops of AHG, centrifuge, gently resuspend, and read for agglutination. Record in the AHG (IAT) column.
9. Validate negative IAT tubes by adding Coombs control cells. A positive reaction here confirms the AHG was active and the wash steps were adequate. A negative reaction invalidates the result and the test must be repeated.

Interpretation

Patients do not generally make antibodies against antigens they themselves carry. So a patient with anti-c antibodies should be c-antigen negative on their own red cells. This phenotype check is an important confirmatory step at the end of identification [2].

Reading an antigram is a process of ruling out antibodies and then ruling in the most likely specificity. Cells that did not react with the patient's plasma are used to exclude antibodies, using homozygous cells wherever possible so a weak antibody is not missed. Cells that did react are examined for a consistent antigen pattern. The two-and-two rule (two positive and two negative cells for the suspected antigen) is the minimum statistical requirement for identification [2]. A worked example of antigram interpretation is covered in a separate article here.

Positive crossmatch with negative screen and identification

Sometimes the antibody screen and identification panel are negative, but the IAT crossmatch with a specific donor unit is positive. Likely explanations:

• Antibody to a low-frequency antigen on the donor unit, not represented on the screening or panel cells.
• Donor red cells already coated with IgG, for example from a previously transfused patient's antibody.
• Clerical or sample error. The wrong unit or wrong patient sample has been crossmatched.

All panel cells positive, but autocontrol and DAT negative

A pan-reactive pattern with a negative autocontrol and a negative direct antiglobulin test (DAT) suggests an antibody to a high-frequency antigen. Specific examples include anti-H seen in the rare Bombay blood group, where the H antigen is absent, and anti-HI. Investigation usually requires reference laboratory support and may include red cell genotyping [6].

All panel cells positive with positive autocontrol and DAT

This pattern points to a warm autoantibody, sometimes with underlying autoimmune hemolytic anemia, or to a delayed serologic / hemolytic transfusion reaction in a recently transfused patient. Adsorption studies (autoadsorption or alloadsorption) are used to remove the autoantibody so any underlying alloantibody can be revealed [1].

Common Pitfalls

A few interferences are worth recognizing:

• Rouleaux — red cells stack like coins in patients with high plasma protein (myeloma, very high fibrinogen). Saline replacement disperses true rouleaux but not true agglutination.
• Cold autoantibody interference — strong cold autoantibodies can mask underlying clinically significant alloantibodies. Pre-warming techniques or cold autoadsorption may be needed.
• Recently transfused patient — circulating donor red cells complicate phenotyping and adsorption strategy.
• Drug-dependent antibodies — some drugs (e.g., cephalosporins, piperacillin) can cause antibodies that react only in the presence of the drug.
• Monoclonal antibody therapies — Drugs like daratumumab (anti-CD38), used to treat multiple myeloma, bind directly to CD38 on reagent red cells. This causes false-positive pan-reactivity at the indirect antiglobulin test (IAT) phase, mimicking a high-frequency alloantibody or warm autoantibody. Laboratories must use specialized techniques, such as treating the panel cells with dithiothreitol (DTT) to destroy the CD38 target, to bypass this interference and detect any underlying clinically significant alloantibodies [10].

Modern Methods and Special Situations

While tube testing remains a foundational reference and teaching method, most clinical laboratories now use gel column agglutination (where cells migrate through a dextran gel) or solid-phase red cell adherence (where red cell membranes are fixed to microplate wells) as their primary routine methods. Both techniques offer higher sensitivity for detecting IgG antibodies, reduce hands-on time, and allow for automated, standardized reading [1].

Red cell genotyping has evolved from a reactive troubleshooting tool into a prophylactic standard of care [6,11]. For patients with sickle cell disease, thalassemia, or a high likelihood of chronic transfusions, extended molecular genotyping is now routinely performed before their first transfusion. This allows for prophylactic extended antigen matching, preventing alloimmunization before it begins. Genotyping also remains critical for resolving complex serology, such as when patients have warm autoantibodies, have been recently transfused, or present with pan-reactivity [6,11].

Frequently Asked Questions (FAQs)

What is the 11-cell panel used for in antibody identification?

An 11-cell panel uses red cells from eleven different group O donors, each with a defined antigen profile. The larger panel gives broader coverage across blood group systems and improves resolution when more than one antibody is present. It is a practical first-line tool for routine antibody identification, balancing antigen coverage and cost. Rare antigens, complex antibody mixtures, or low-frequency antigen antibodies may still require additional panels or molecular methods.

What does "rule out" mean during antibody identification?

Rule-out is the process of excluding antibodies that the panel reactions show are unlikely to be present. If the patient's plasma fails to react with a panel cell that is homozygous positive for a given antigen, the antibody to that antigen can usually be ruled out. Homozygous cells are preferred for rule-out because antibodies showing a dosage effect may react weakly or not at all with heterozygous cells, risking a false negative exclusion [2].

Why must panel cells be group O?

Group O red cells lack A and B antigens. This prevents the patient's naturally occurring anti-A or anti-B from interfering with the reactions, allowing antibodies to other blood group antigens to be detected clearly.

Are all detected antibodies clinically significant?

No. Antibodies that react at 37°C and at the antiglobulin phase, and are IgG class, are usually considered clinically significant because they can destroy transfused red cells or cross the placenta. Cold-reacting IgM antibodies such as anti-Lewis, anti-P1, anti-M (cold only), and anti-N are usually not clinically significant in transfusion [1,8].

What if a patient's antibody cannot be identified?

Unresolved cases are referred to a reference laboratory. Additional approaches include enzyme-treated panels, adsorption-elution studies, antibody titration, and red cell genotyping [6,7]. In urgent transfusion situations, the safest available antigen-matched units are issued under clinical guidance.

Glossary of Related Medical Terms

• Agglutination — visible clumping of red blood cells when antibodies bridge antigens on neighboring cells. The endpoint of most blood bank tests.
• Alloantibody — an antibody made by a person against red cell antigens they themselves lack, after exposure through transfusion or pregnancy.
• Antigram — the printed grid used to record reactions of patient plasma against each panel cell, mapped against the antigens those cells carry.
• Autoantibody — an antibody that targets antigens on the person's own red cells.
• Autocontrol — a tube that tests the patient's plasma against the patient's own red cells. Helps tell auto- from alloantibodies apart.
• Coombs control cells (CCC) — IgG-coated red cells added at the end of an antiglobulin test to confirm the anti-human globulin reagent is working.
• Direct antiglobulin test (DAT) — a test for antibodies already bound to a patient's red cells in the body.
• Dosage effect — some antibodies react more strongly with cells that carry two copies of an antigen (homozygous) than with cells carrying one copy (heterozygous).
• Hemolysis — destruction of red cells, here meaning antibody-mediated red cell breakdown.
• Hemolytic disease of the fetus and newborn (HDFN) — destruction of fetal/newborn red cells by maternal IgG alloantibodies that cross the placenta.
• Hemolytic transfusion reaction (HTR) — destruction of transfused red cells by recipient antibodies. Can be immediate (acute) or delayed.
• Indirect antiglobulin test (IAT) — a test for antibodies free in plasma that can bind to test red cells in vitro.
• Isoagglutinins — naturally occurring ABO antibodies (anti-A, anti-B) not requiring prior red cell exposure.
• Low ionic strength solution (LISS) — a reagent that speeds up antibody binding by lowering the ionic environment around red cells.
• Panel cells — pre-typed group O red cells with known antigen profiles, used for identification.
• Zygosity (homozygous / heterozygous) — whether a cell carries two copies of the same antigen gene or one copy of each allele. Important for the dosage effect.

Disclaimer: This protocol is for educational purposes only. Local laboratory standard operating procedures take precedence. It is not intended to be a substitute for informed professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional for clinical decision-making. While the information presented here is derived from credible medical sources and is believed to be accurate and up-to-date, it is not guaranteed to be complete or error-free. See additional information.

References

1. American Association of Blood Banks (AABB). Technical Manual, 21st Edition, 2023.
2. British Committee for Standards in Haematology, Milkins, C., Berryman, J., Cantwell, C., Elliott, C., Haggas, R., Jones, J., Rowley, M., Williams, M., & Win, N. (2013). Guidelines for pre-transfusion compatibility procedures in blood transfusion laboratories. British Committee for Standards in Haematology. Transfusion medicine (Oxford, England), 23(1), 3–35. https://doi.org/10.1111/j.1365-3148.2012.01199.x
3. Bain BJ, Bates I, Laffan MA. Dacie and Lewis Practical Haematology: Expert Consult: Online and Print 12th Edition (Elsevier). 2016.
4. Dean L. Blood Groups and Red Cell Antigens [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2005. Available from: https://www.ncbi.nlm.nih.gov/books/NBK2261/
5. Daniels, G. (2013). Human blood groups (3rd ed.). Wiley-Blackwell.
6. Westhoff C. M. (2019). Blood group genotyping. Blood, 133(17), 1814–1820. https://doi.org/10.1182/blood-2018-11-833954
7. Sandler, S. G., Chen, L. N., & Flegel, W. A. (2017). Serological weak D phenotypes: a review and guidance for interpreting the RhD blood type using the RHD genotype. British journal of haematology, 179(1), 10–19. https://doi.org/10.1111/bjh.14757
8. Delaney, M., Wendel, S., Bercovitz, R. S., Cid, J., Cohn, C., Dunbar, N. M., Apelseth, T. O., Popovsky, M., Stanworth, S. J., Tinmouth, A., Van De Watering, L., Waters, J. H., Yazer, M., Ziman, A., & Biomedical Excellence for Safer Transfusion (BEST) Collaborative (2016). Transfusion reactions: prevention, diagnosis, and treatment. Lancet (London, England), 388(10061), 2825–2836. https://doi.org/10.1016/S0140-6736(15)01313-6
9. Tormey, C. A., & Hendrickson, J. E. (2019). Transfusion-related red blood cell alloantibodies: induction and consequences. Blood, 133(17), 1821–1830. https://doi.org/10.1182/blood-2018-08-833962
10. Chapuy, C. I., Nicholson, R. T., Aguad, M. D., Chapuy, B., Laubach, J. P., Richardson, P. G., Doshi, P., & Kaufman, R. M. (2015). Resolving the daratumumab interference with blood compatibility testing. Transfusion, 55(6 Pt 2), 1545–1554. https://doi.org/10.1111/trf.13069
11. Chou, S. T., Alsawas, M., Fasano, R. M., Field, J. J., Hendrickson, J. E., Howard, J., Kameka, M., Kwiatkowski, J. L., Pirenne, F., Shi, P. A., Stowell, S. R., Thein, S. L., Westhoff, C. M., Wong, T. E., & Akl, E. A. (2020). American Society of Hematology 2020 guidelines for sickle cell disease: transfusion support. Blood advances, 4(2), 327–355. https://doi.org/10.1182/bloodadvances.2019001143